Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK5211 in hip fracture recovery
NCT02578095Phase 2Completed
- Sponsor
- Viking Therapeutics
- Start
- Oct 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of Ligandrol in hip fracture (4 arms), sponsored by Viking Therapeutics. Primary endpoint: Efficacy in Hip Fracture Patients Confirmed by DXA Scan at 12 weeks. Started Oct 2015; status: completed.
02
Drugs
Ligandrol
03
Conditions
hip fracture
Beyond the preview
Go deeper on NCT02578095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578095.